{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:02:51Z","timestamp":1793689371003,"version":"4.5.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","award":["ANR-23-IAIIU-0010"],"award-info":[{"award-number":["ANR-23-IAIIU-0010"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neurol.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:02:11Z","timestamp":1744318931000},"page":"450-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted therapies in epilepsies"],"prefix":"10.1016","volume":"181","author":[{"given":"S.","family":"Auvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.neurol.2025.04.003_bib0010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","article-title":"Drug resistance in epilepsy","volume":"22","author":"Perucca","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0015","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00415-023-12165-4","article-title":"Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011\u20132021","volume":"271","author":"Shankar","year":"2024","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2025.04.003_bib0020","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/epi.17332","article-title":"Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges, and suggestions for continued progress","volume":"63","author":"Knowles","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1528-1167.2006.00569.x","article-title":"Proposed criteria for referral and evaluation of children for epilepsy surgery: recommendations of the subcommission for pediatric epilepsy surgery","volume":"47","author":"Cross","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0030","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/brain\/awq143","article-title":"Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)","volume":"133","author":"Mills","year":"2010","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.003_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jimd.12045","article-title":"The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: a common epileptic encephalopathy","volume":"42","author":"Coughlin","year":"2019","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.003_bib0040","doi-asserted-by":"crossref","first-page":"115069","DOI":"10.1016\/j.celrep.2024.115069","article-title":"Restricting lysine normalizes toxic catabolites associated with ALDH7A1 deficiency in cells and mice","volume":"43","author":"Johal","year":"2024","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ymgme.2022.02.005","article-title":"Timing of therapy and neurodevelopmental outcomes in 18 families with pyridoxine-dependent epilepsy","volume":"135","author":"Tseng","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.neurol.2025.04.003_bib0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0022-3999(94)90073-6","article-title":"Self-esteem and behavioral-adjustment in children with epilepsy and children with diabetes","volume":"38","author":"Hoare","year":"1994","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.neurol.2025.04.003_bib0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/brain\/awp336","article-title":"Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder","volume":"133","author":"Leen","year":"2010","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.neurol.2025.04.003_bib0060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1528-1157.2003.54902.x","article-title":"Absence epilepsy with onset before age three years: a heterogeneous and often severe condition","volume":"44","author":"Chaix","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1528-1157.43.s.3.3.x","article-title":"Epileptic syndromes in childhood: clinical features, outcomes, and treatment","volume":"43","author":"Camfield","year":"2002","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.neurol.2025.04.003_bib0070","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/dmcn.13167","article-title":"Use of modified Atkins diet in glucose transporter type 1 deficiency syndrome","volume":"58","author":"Amalou","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.003_bib0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/archpedi.1997.02170390042008","article-title":"Long-term psychosocial outcome in typical absence epilepsy\u00a0\u2013\u00a0sometimes a wolf in sheeps\u2019 clothing","volume":"151","author":"Wirrell","year":"1997","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.003_bib0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/epi4.13110","article-title":"Exploring ketogenic diet resistance in glucose transporter type 1 deficiency syndrome: a comprehensive review and critical appraisal","volume":"10","author":"Falsaperla","year":"2025","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"issue":"10056","key":"10.1016\/j.neurol.2025.04.003_bib0090","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2025.04.003_bib0095","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/epi.14551","article-title":"Lack of response to quinidine in KCNT1-related neonatal epilepsy","author":"Numis","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/ana.27213","article-title":"Fluoxetine treatment in epilepsy of infancy with migrating focal seizures due to KCNT1 variants: an open label study","author":"Trivisano","year":"2025","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/acn3.542","article-title":"Depdc5 knockdown causes mTOR-dependent motor hyperactivity in zebrafish","volume":"5","author":"de Calbiac","year":"2018","journal-title":"Ann Clin Trans Neurol"},{"issue":"17","key":"10.1016\/j.neurol.2025.04.003_bib0110","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/hmg\/ddz123","article-title":"Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice","volume":"28","author":"Yuskaitis","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.003_bib0115","doi-asserted-by":"crossref","first-page":"e1006536","DOI":"10.1371\/journal.pgen.1006536","article-title":"Molecular mechanism of disease-associated mutations in the pre-M1 helix of NMDA receptors and potential rescue pharmacology","volume":"13","author":"Ogden","year":"2017","journal-title":"PLoS Genet"},{"issue":"Suppl. 1","key":"10.1016\/j.neurol.2025.04.003_bib0120","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0140-6736(15)60380-4","article-title":"Effect of a GRIN2A de novo mutation associated with epilepsy and intellectual disability on NMDA receptor currents and Mg(2+) block in cultured primary cortical neurons","volume":"385","author":"Marwick","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.003_bib0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/acn3.39","article-title":"GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine","volume":"1","author":"Pierson","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2025.04.003_bib0130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuropharm.2017.05.017","article-title":"GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors","volume":"123","author":"Mullier","year":"2017","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.neurol.2025.04.003_bib0135","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X18787946","article-title":"Atypical rett syndrome and intractable epilepsy with novel GRIN2B mutation","volume":"5","author":"Kyriakopoulos","year":"2018","journal-title":"Child Neurol Open"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.24128","article-title":"KCNT1 gain of function in 2 epilepsy phenotypes is reversed by Quinidine","volume":"75","author":"Milligan","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0145","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ana.24520","article-title":"Quinidine in the treatment of KCNT1-positive epilepsies","volume":"78","author":"Mikati","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2025.04.003_bib0150","doi-asserted-by":"crossref","first-page":"106944","DOI":"10.1016\/j.yebeh.2020.106944","article-title":"Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy","volume":"105","author":"Lossius","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.003_bib0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.24229","article-title":"Targeted treatment of migrating partial seizures of infancy with Quinidine","volume":"76","author":"Bearden","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.003_bib0160","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1212\/WNL.0000000000004769","article-title":"Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine","volume":"90","author":"Mullen","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.003_bib0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1684\/epd.2019.1026","article-title":"Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations","volume":"21","author":"Yoshitomi","year":"2019","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.neurol.2025.04.003_bib0170","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/epi.16480","article-title":"KCNT1-related epilepsy: an international multicenter cohort of 27 pediatric cases","author":"Borlot","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0175","doi-asserted-by":"crossref","first-page":"35080","DOI":"10.1038\/srep35080","article-title":"The anticonvulsant retigabine suppresses neuronal K(V)2-mediated currents","volume":"6","author":"Stas","year":"2016","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.neurol.2025.04.003_bib0180","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1523\/JNEUROSCI.5176-14.2015","article-title":"Potent KCNQ2\/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus","volume":"35","author":"Kalappa","year":"2015","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.003_bib0185","doi-asserted-by":"crossref","first-page":"e0150095","DOI":"10.1371\/journal.pone.0150095","article-title":"Retigabine, a K(v)7.2\/K(v)7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations","volume":"11","author":"Ihara","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0190","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/epi.12984","article-title":"Early and effective treatment of KCNQ2 encephalopathy","volume":"56","author":"Pisano","year":"2015","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.003_bib0195","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/epi.13596","article-title":"Rapid and safe response to low-dose carbamazepine in neonatal epilepsy","volume":"57","author":"Sands","year":"2016","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.neurol.2025.04.003_bib0200","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/epi.12657","article-title":"Antiepileptic activity of preferential inhibitors of persistent sodium current","volume":"55","author":"Anderson","year":"2014","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.neurol.2025.04.003_bib0205","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1073\/pnas.1615774114","article-title":"CaMKII modulates sodium current in neurons from epileptic Scn2a mutant mice","volume":"114","author":"Thompson","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2025.04.003_bib0210","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.04.003_bib0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/epi.16438","article-title":"Biological concepts in human sodium channel epilepsies and their relevance in clinical practice","author":"Brunklaus","year":"2020","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/epd.2018.1001","article-title":"Lacosamide for SCN2A-related intractable neonatal and infantile seizures","volume":"20","author":"Hadar","year":"2018","journal-title":"Epileptic Disord"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.25188","article-title":"Mutations in SCN3A cause early infantile epileptic encephalopathy","volume":"83","author":"Zaman","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0230","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/epi.14037","article-title":"A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy","volume":"59","author":"Atkin","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0235","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/epi.14196","article-title":"The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy","volume":"59","author":"Baker","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neurol.2025.04.003_bib0240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s13311-015-0386-2","article-title":"Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach (vol 13, pg 192, 2016)","volume":"13","author":"Boerma","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.neurol.2025.04.003_bib0245","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.13031","article-title":"Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex","volume":"56","author":"Rensing","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.23943","article-title":"TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice","volume":"74","author":"Abs","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.003_bib0255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurol.2022.12.007","article-title":"mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations","volume":"179","author":"Auvin","year":"2023","journal-title":"Rev Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2025.04.003_bib0270","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Human Mol Genet"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0275","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.24368","article-title":"Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations","volume":"77","author":"Baulac","year":"2015","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0280","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00401-019-02061-5","article-title":"Dissecting the genetic basis of focal cortical dysplasia: a large cohort study","volume":"138","author":"Baldassari","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0285","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI99384","article-title":"Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy","volume":"128","author":"Ribierre","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.neurol.2025.04.003_bib0290","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.24126","article-title":"Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations","volume":"75","author":"Scheffer","year":"2014","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.04.003_bib0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acn3.51505","article-title":"Sirolimus for epileptic seizures associated with focal cortical dysplasia type II","volume":"9","author":"Kato","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.003_bib0300","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1111\/jnc.16103","article-title":"Variant-specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy","volume":"168","author":"Jia","year":"2024","journal-title":"J Neurochem"},{"issue":"12","key":"10.1016\/j.neurol.2025.04.003_bib0305","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1093\/brain\/awac006","article-title":"Gene variant effects across sodium channelopathies predict function and guide precision therapy","volume":"145","author":"Brunklaus","year":"2022","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neurol.2025.04.003_bib0310","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/epi4.12997","article-title":"Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis","volume":"9","author":"Zhang","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neurol.2025.04.003_bib0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.04.016","article-title":"Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex","volume":"80","author":"Zhang","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"11","key":"10.1016\/j.neurol.2025.04.003_bib0320","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/epi.17396","article-title":"GluN2C selective inhibition is a target to develop new antiepileptic compounds","volume":"63","author":"Gataullina","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0325","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1038\/ncomms5563","article-title":"Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model","volume":"5","author":"Lozovaya","year":"2014","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.neurol.2025.04.003_bib0330","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ng.2441","article-title":"De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy","volume":"44","author":"Barcia","year":"2012","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.neurol.2025.04.003_bib0335","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on nosology and definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2025.04.003_bib0340","doi-asserted-by":"crossref","first-page":"110139","DOI":"10.1016\/j.yebeh.2024.110139","article-title":"Pharmacotherapeutic strategies for drug-resistant epilepsy in children","volume":"161","author":"Auvin","year":"2024","journal-title":"Epilepsy Behav"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:28:08Z","timestamp":1746808088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725004953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0035378725004953"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.04.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies in epilepsies","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}